PMID- 12939552
OWN - NLM
STAT- MEDLINE
DCOM- 20040512
LR  - 20190819
IS  - 1346-9843 (Print)
IS  - 1346-9843 (Linking)
VI  - 67
IP  - 9
DP  - 2003 Sep
TI  - Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive 
      cardiomyopathy.
PG  - 763-7
AB  - Percutaneous transluminal septal myocardial ablation (PTSMA) is a new therapeutic 
      option for patients with hypertrophic obstructive cardiomyopathy (HOCM). In the 
      present study, the acute and follow-up results of PTSMA were evaluated. From 
      August 1997 to March 2003 27 medically refractory patients (New York Heart 
      Association (NYHA) functional class 2.9+/-0.6) with HOCM underwent PTSMA. The 
      target septal branch was determined by probationary ballooning in 3 and by 
      myocardial contrast echocardiography in 24 patients. The mean resting left 
      ventricular outflow tract pressure gradient (PG) was reduced from 70+/-44 to 
      24+/-22 mmHg (p<0.0001); the peak concentration of creatine kinase was 1545+/-686 
      IU/L. Although transient trifascicular block was observed in 14 patients, 
      permanent pacemaker implantation was not required. There were no major adverse 
      cardiac events during the hospital stay; the mean clinical follow-up was 
      2.2+/-1.7 years. Repeated PTSMA was needed in 1 patient; however, symptomatic 
      improvement had been well preserved in all patients (NYHA class 1.2+/-0.4). 
      Follow-up echocardiographic examination showed sustained improvement in PG, 
      septal and left ventricular posterior wall thicknesses, and the grade of systolic 
      anterior movement and regurgitation of the mitral valve. In conclusion, PTSMA is 
      a safe and effective therapeutic option for medically refractory patients with 
      HOCM.
FAU - Tsuchikane, Etsuo
AU  - Tsuchikane E
AD  - Department of Cardiology, Osaka Medical Center for Cancer and Cardiovascular 
      Diseases, Osaka, Japan. dokincha@aioros.ocn.ne.jp
FAU - Takeda, Yoshihiro
AU  - Takeda Y
FAU - Kobayashi, Tohru
AU  - Kobayashi T
FAU - Yachiku, Kenji
AU  - Yachiku K
FAU - Nasu, Kenya
AU  - Nasu K
FAU - Kobayashi, Yoshiki
AU  - Kobayashi Y
FAU - Matsumoto, Hiroaki
AU  - Matsumoto H
FAU - Awata, Nobuhisa
AU  - Awata N
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 3K9958V90M (Ethanol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiomyopathy, Hypertrophic/diagnostic imaging/*therapy
MH  - *Catheterization
MH  - Echocardiography
MH  - Ethanol/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Septum/*drug effects
MH  - Humans
MH  - Inpatients
MH  - Male
MH  - Middle Aged
MH  - Retreatment
MH  - Treatment Outcome
EDAT- 2003/08/27 05:00
MHDA- 2004/05/13 05:00
CRDT- 2003/08/27 05:00
PHST- 2003/08/27 05:00 [pubmed]
PHST- 2004/05/13 05:00 [medline]
PHST- 2003/08/27 05:00 [entrez]
AID - 10.1253/circj.67.763 [doi]
PST - ppublish
SO  - Circ J. 2003 Sep;67(9):763-7. doi: 10.1253/circj.67.763.